Skip to main content

Branded

  • FDA approves removal of boxed label warning from Pfizer’s Chantix

    NEW YORK — The U.S. Food and Drug Administration approved removal of the boxed label warning regarding serious neuropsychiatric events from Pfizer’s Chantix (varenicline).

  • Lilly, Boehringer Ingelheim launch Lantus follow-on Basaglar

    INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals on Thursday announced the launch and availability of their Basaglar. The drug is a follow-on insulin to U-100 insulin glargine Lantus and is a long-acting insulin with an amino acid sequence identical to that of Lantus. 
     

  • Rexall welcomes expansion of 13 vaccinations available through retail pharmacy in Ontario

    MISSISSAUGA, Ontario  — Rexall pharmacists in Ontario are now permitted to administer 13 more vaccinations that prevent shingles, hepatitis and cervical cancer, as well as several vaccines to people that are travelling overseas.

  • Walgreens releases first flu index for the season

    DEERFIELD, Ill.  — Walgreens on Thursday launched its first Flu Index for the 2016-17 season, a weekly report that ranks the top markets and states for flu activity in the U.S. It's the third year for Walgreens' Flu Index, and this year will include Puerto Rico for the first time.

  • FDA approves Pfizer’s eczema treatment Eucrisa

    SILVER SPRING, Md. — The Food and Drug Administration on Wednesday announced its approval of Pfizer’s Eucrisa (crisaborole). The ointment is indicated to treat mild to moderate eczema in patients two years of age and older. 
     

  • Lilly rolls out insulin discount program

    INDIANAPOLIS, Ind. —  Eli Lilly & Co. has outlined a new initiative, set to begin Jan. 1, 2017, that will offer access to Lilly insulin at discounted prices to patients via Blink Health’s mobile and web platforms through a partnership with Express Scripts. 
     

  • FDA approves Synjardy XR from Lilly, Boehringer Ingelheim

    RIDGEFIELD, Conn. and INDIANAPOLIS — The Food and Drug Administration has approved Eli Lilly & Co.’s and Boehringer Ingelheim’s Synjardy XR (empagliflozin and metformin hydrochloride) extended-release tablets. The drug is indicated to improve blood sugar in adults with Type 2 diabetes when both empagliflozin and metformin can be taken. 
     

  • Lilly, AstraZeneca to team on Alzheimer’s treatment development

    INDIANAPOLIS — Eli Lilly and Co. and AstraZeneca are teaming up to co-develop a potential disease-modifying treatment for Alzheimer’s disease, the companies announced Friday. 
     
    The focus of the initiative, which will see Lilly making an upfront payment of $30 million to AstraZeneca, is an antibody called MEDI1814, which can potentially slow the progression of the illness and is currently in Phase 1 trials. 
     
X
This ad will auto-close in 10 seconds